Treats hypertension. ANDA 90416, held by Glenmark Pharms Ltd. Moexipril Hydrochloride.
As of Nov 16, 2026, ANDA 90416 (Moexipril Hydrochloride), held by Glenmark Pharms Ltd, was first approved by FDA on Mar 30, 2010, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Moexipril hydrochloride tablets are indicated for treatment of patients with hypertension. They may be used alone or in combination with thiazide diuretics. In using moexipril hydrochloride tablets, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that moexipril hydrochloride tablets do not have a similar risk (see WARNINGS ).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 30, 2010 | Original application | Approved | None posted |
| Moexipril Hydrochloride7.5MG · tablet;oral | Moexipril Hydrochloride | Rx |
| Moexipril Hydrochloride15MG · tablet;oral | Moexipril Hydrochloride | Rx |
| Mar 2, 2015 | Supplement 2Labeling | Approved | None posted |
| Mar 2, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 29, 2011 | Supplement 1Labeling | Approved | None posted |
| Mar 30, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters